Pancreatic Cancer Research

ResearcherLeiden University Medical CenterActive in the last 2 years

J. Sven D. Mieog

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3649-8504; OpenAlex author ID A5024409239, A5103736918, A5103852120, A5120964299. Sources: ClinicalTrials.gov.

Their work

Papers
68 (first author 1, last author 18)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
192
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 4 papers · 2018: 3 papers · 2019: 6 papers · 2020: 6 papers · 2021: 5 papers · 2022: 5 papers · 2023: 11 papers, 1 trial · 2024: 9 papers · 2025: 10 papers · 2026: 6 papers

Papers 50 of 68

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Co-author DOI 10.1016/j.hpb.2025.12.001↗
  3. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  4. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  5. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  6. Association Between Computed Tomography-Based AI-Derived Body Composition and Survival in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.14309/ajg.0000000000003896↗
  7. Both skeletal muscle index and muscle attenuation are associated with frailty in preoperative older patients with pancreatic cancer. Co-author DOI 10.1016/j.clnu.2025.11.004↗
  8. Tumor gene expression is associated with venous thromboembolism in patients with ductal pancreatic adenocarcinoma. Co-author DOI 10.1016/j.thromres.2024.109240↗
  9. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  10. Revolutionizing Solid Tumor Surgery with Fibroblast Activation Protein (FAP)-Targeted Imaging Probes for a Fluorescence-Guided Surgery of Pancreatic Cancer. Co-author DOI 10.1021/acs.bioconjchem.5c00218↗
  11. Evaluation of tumor targets selected from public genomic databases for imaging of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-025-00517-1↗
  12. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  13. Perineural Invasion is an Important Prognostic Factor in Patients With Radically Resected (R0) and Node-negative (pN0) Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006320↗
  14. Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. Co-author DOI 10.1097/sla.0000000000006910↗
  15. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  16. Computer-Aided Decision Support and 3D Models in Pancreatic Cancer Surgery: A Pilot Study. Co-author DOI 10.3390/jcm14051567↗
  17. Screening for pancreatic cancer in high-risk individuals using MRI: optimization of scan techniques to detect small lesions. Co-author DOI 10.1007/s10689-024-00394-z↗
  18. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study. Co-author DOI 10.1093/jnci/djae070↗
  19. The Added Value of Blood Glucose Monitoring in High-Risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1097/mpa.0000000000002335↗
  20. Poor Prognostic Factors in Long-Term Survivors of Resected Pancreatic Ductal Adenocarcinoma: An International, Multicenter Cohort Study. Co-author DOI 10.1097/sla.0000000000006539↗
  21. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Co-author DOI 10.1245/s10434-023-14650-6↗
  22. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone f… Co-author DOI 10.1245/s10434-023-14704-9↗
  23. Surgical Outcome After Distal Pancreatectomy With and Without Portomesenteric Venous Resection in Patients with Pancreatic Adenocarcinoma: A Transatlantic Eval… Co-author DOI 10.1245/s10434-024-15932-3↗
  24. ASO Author Reflections: Distal Pancreatectomy With and Without Portomesenteric Venous Resection for Pancreatic Adenocarcinoma: A Transatlantic Evaluation of Pa… Co-author DOI 10.1245/s10434-024-16021-1↗
  25. Operation Volume in Pancreatic Cancer Surgery: How Long Will We Keep Looking the Other Way? Co-author DOI 10.20344/amp.21621↗
  26. Prediction of Biomarker Expression on Primary Pancreatic Ductal Adenocarcinoma Tissues Using Fine-Needle Biopsies: Paving the Way for a Patient-Tailored Molecu… Co-author DOI 10.1007/s40291-022-00635-w↗
  27. The yield of staging laparoscopy for resectable and borderline resectable pancreatic cancer in the PREOPANC randomized controlled trial. Co-author DOI 10.1016/j.ejso.2022.12.011↗
  28. Practice variation in venous resection during pancreatoduodenectomy for pancreatic cancer: A nationwide cohort study. Last author DOI 10.1016/j.surg.2023.06.012↗
  29. Added value of digital FDG-PET/CT in disease staging and restaging in patients with resectable or borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2023.101909↗
  30. Surveillance for Pancreatic Cancer in High-Risk Individuals Leads to Improved Outcomes: A Propensity Score-Matched Analysis. Co-author DOI 10.1053/j.gastro.2023.02.032↗
  31. Increasing Systemic Immune-inflammation Index During Treatment in Patients With Advanced Pancreatic Cancer is Associated With Poor Survival: A Retrospective, M… Co-author DOI 10.1097/sla.0000000000005865↗
  32. Intraoperative Ultrasound During Surgical Exploration in Patients with Pancreatic Cancer and Vascular Involvement (ULTRAPANC): A Prospective Multicenter Study. Last author DOI 10.1245/s10434-023-13112-3↗
  33. Intraoperative Molecular Fluorescence Imaging of Pancreatic Cancer by Targeting Vascular Endothelial Growth Factor: A Multicenter Feasibility Dose-Escalation S… Co-author DOI 10.2967/jnumed.121.263773↗
  34. Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using a Fluorescently Labelled Anti-CEA Nanobody Probe: A Preclinical Study. Last author DOI 10.3390/biom13040618↗
  35. Consensus Statement on the Use of Near-Infrared Fluorescence Imaging during Pancreatic Cancer Surgery Based on a Delphi Study: Surgeons' Perspectives on Curren… Last author DOI 10.3390/cancers15030652↗
  36. Venous Thromboembolism and Primary Thromboprophylaxis in Perioperative Pancreatic Cancer Care. Co-author DOI 10.3390/cancers15143546↗
  37. Author response to: Venous wedge and segment resection during pancreatoduodenectomy for pancreatic cancer: impact on short- and long-term outcomes in a nationw… Last author DOI 10.1093/bjs/znac060↗
  38. Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderl… Co-author DOI 10.1097/sla.0000000000004313↗
  39. Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Prospective Follow-Up. Co-author DOI 10.1200/jco.22.00194↗
  40. High Systemic Immune Inflammation Index Is Associated With Low Skeletal Muscle Quantity in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2022.827755↗
  41. Single fiber reflectance spectroscopy for pancreatic cancer detection during endoscopic ultrasound guided fine needle biopsy: a prospective cohort study. Last author DOI 10.7150/ijms.65364↗
  42. Incidence, timing and risk factors of venous thromboembolic events in patients with pancreatic cancer. Last author DOI 10.1016/j.thromres.2021.08.002↗
  43. Venous wedge and segment resection during pancreatoduodenectomy for pancreatic cancer: impact on short- and long-term outcomes in a nationwide cohort analysis. Last author DOI 10.1093/bjs/znab345↗
  44. Resection of the Portal-Superior Mesenteric Vein in Pancreatic Cancer: Pathological Assessment and Recurrence Patterns. Last author DOI 10.1097/mpa.0000000000001897↗
  45. An Immunohistochemical Evaluation of Tumor-Associated Glycans and Mucins as Targets for Molecular Imaging of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13225777↗
  46. Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy. Last author DOI 10.3390/cancers13236088↗
  47. International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.ejso.2019.12.023↗
  48. Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment. Co-author DOI 10.1038/s41598-020-73242-6↗
  49. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis. Last author DOI 10.1080/1354750x.2020.1725786↗
  50. Treatment and Survival of Elderly Patients with Stage I-II Pancreatic Cancer: A Report of the EURECCA Pancreas Consortium. Last author DOI 10.1245/s10434-020-08539-x↗

Trials 1

  1. Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW) Principal investigator NCT05784311↗

Closest collaborators

The 25 strongest of 192 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bert A. Bonsing · 39 shared papers, 2014–2025 · strength 4.67
  2. Alexander L. Vahrmeijer · 29 shared papers, 2014–2025 · strength 3.66
  3. Marc G. Besselink · 20 shared papers, 2020–2026 · strength 2.88
  4. Bas Groot Koerkamp · 21 shared papers, 2019–2026 · strength 2.86
  5. Casper H.J. van Eijck · 18 shared papers, 2017–2026 · strength 2.31
  6. Jesse V. Groen · 17 shared papers, 2018–2025 · strength 2.19
  7. Ignace H. J. T. de Hingh · 12 shared papers, 2021–2026 · strength 1.80
  8. Gijs A. Patijn · 9 shared papers, 2022–2026 · strength 1.41
  9. Izaak Quintus Molenaar · 9 shared papers, 2021–2026 · strength 1.38
  10. Martijn W.J. Stommel · 9 shared papers, 2021–2026 · strength 1.34
  11. Rutger‐Jan Swijnenburg · 13 shared papers, 2016–2023 · strength 1.22
  12. Hjalmar C. van Santvoort · 8 shared papers, 2021–2026 · strength 1.21
  13. Nynke Michiels · 7 shared papers, 2021–2025 · strength 1.20
  14. Thomas F. Stoop · 7 shared papers, 2024–2026 · strength 1.16
  15. Christopher Lee Wolfgang · 7 shared papers, 2020–2026 · strength 1.07
  16. Martin N.J.M. Wasser · 7 shared papers, 2021–2024 · strength 1.07
  17. Jeanin Elise van Hooft · 6 shared papers, 2022–2026 · strength 1.05
  18. Ruben D. Houvast · 6 shared papers, 2021–2025 · strength 1.03
  19. Geert Kazemier M · 6 shared papers, 2024–2026 · strength 0.98
  20. Monique Esther van Leerdam · 5 shared papers, 2022–2026 · strength 0.98
  21. Sebastiaan Festen · 6 shared papers, 2022–2026 · strength 0.92
  22. Peter J.K. Kuppen · 7 shared papers, 2016–2025 · strength 0.84
  23. Roeland F. de Wilde · 5 shared papers, 2024–2026 · strength 0.83
  24. Labrinus van Manen · 6 shared papers, 2017–2023 · strength 0.77
  25. Hans F. A. Vasen · 5 shared papers, 2017–2024 · strength 0.76

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.